Treatment of Cardiovascular Diseases - South Korea
South Korea- The revenue in the Treatment of Cardiovascular Diseases market in South Korea is expected to reach US$7.06bn in 2024.
- Furthermore, it is projected to show an annual growth rate (CAGR 2024-2029) of 5.41%, resulting in a market volume of US$9.19bn by 2029.
- When compared globally, United States is expected to generate the highest revenue of US$136.00bn in 2024.
- South Korea is at the forefront of innovative cardiovascular treatments, with a strong focus on technological advancements and personalized medicine.
Definition:
Treatments of Cardiovascular Diseases refers to the treatment of patients with diseases or disorders that affect the circulatory system, including coronary artery disease, heart disease, and stroke. During their stay in the hospital, patients are provided with necessary surgical procedures, medication management, and any medical intervention that is needed to manage their symptoms, prevent complications, and further progression of the disease, thus improving their overall health and well-being.
Additional information:
The Treatments of Cardiovascular Diseases market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.
In-Scope
- Diagnostic testing
- Medication received during inpatient treatments
- Continuous monitoring, such as tracking heart rate or blood pressure
- Interventional procedures, such as angioplasty or stenting
Out-Of-Scope
- Long-term rehabilitative care
- Home-based rehabilitative care
